Confluence Pharmaceuticals

Confluence Pharmaceuticals develops novel treatments for core social and communication impairments in Autism, Fragile X Syndrome, and related disorders.

Health and bio Consumer and social

Latest funding

Series B+ · June 17, 2022

Amount not disclosed in a source on record.

Funding history ↓

Website: confluencepharma.com.

Categories: Health and bio Consumer and social.

Stage: Series B+.

Last round: Jun 17, 2022 · 1,609 days ago.

On Recent Funding since: Nov 8, 2026.

Signals

Website registeredJun 24, 2010 (16 years old)

Funding rounds

June 17, 2022
Series B+ · amount undisclosed
Source: fundraisingfox.com
June 24, 2010
Website created

Founders and team

BW
Boyd W. Sturdevant Chairman & Founder

source: confluencepharma.com
SL
Steven L. Johns President & Founder

source: confluencepharma.com

Companies like Confluence Pharmaceuticals

KKinoxis TherapeuticsSeries B+ · Aug 2024
IInStride Health$30M Series B+ · Jun 2026
NNoema PharmaSeries B+ · Nov 2025
BButterfly Learnings$6.7M Series A · Aug 2026
SSyremis Therapeutics$165M Series A · Dec 2025
TTinkeso Therapeutics

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/confluence-pharmaceuticals (get a free API key).